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Abstract
Background: HIV and tuberculosis (TB) are the most common causes of death in South Africa. Antiretroviral therapy (ART)
programmes should have had an impact on mortality rates. This study describes the impact of HIV, a Wellness (HIV/ART)
programme and TB on population-wide trends in mortality and causes of death among South African platinum miners, from
before the HIV epidemic into the ART era.
Methodology/Principal Findings: Retrospective analysis was conducted using routinely-collected data from an open
cohort. Mortality and causes of death were determined from multiple sources, including cardiorespiratory autopsy records.
All-cause and cause-specific mortality rates were calculated by calendar year. 41,665 male miners were observed for 311,938
person years (py) with 3863 deaths. The all-cause age-standardised mortality rate increased from 5.9/1000py in 1992 to 20.2/
1000py in 2002. Following ART rollout in 2003, annual mortality rates fluctuated between 12.4/1000py and 19.3/1000py in
the subsequent 7 years. Half of all deaths were HIV-related and 21% were caused by TB. Half (50%) of miners who died of
HIV after ART rollout had never been registered on the Wellness programme. TB was the most common cause of death in
HIV positive miners, increasing from 28% of deaths in the pre-ART period to 41% in the post-ART period.
Conclusions/Significance: This population-based cohort experienced a rapid increase in mortality from 1996 to 2003 due to
increases in HIV and TB mortality. Following ART rollout there was a decrease in mortality, but a steady decrease has not
been sustained. Possible explanations for these trends include the changing composition of the workforce, maturation of
the HIV epidemic, insufficient uptake of ART and an increase in the proportion of deaths due to TB. In order to make
a significant and sustained reduction in mortality in this population, expanding and integrating HIV and TB care and
treatment is essential.
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Introduction
While mortality rates worldwide have declined over the past two
decades, there have been substantial increases in adult mortality in
South Africa, mainly due to HIV and tuberculosis (TB). [1] Since
the widespread implementation of antiretroviral therapy (ART)
programmes, six published reports from sub-Saharan Africa on
the impact of ART at a population level have demonstrated
reduced mortality. [2–7] ART has not yet reached everyone in
need, however, and HIV mortality rates are still unacceptably
high. [8] ART has also been associated with reductions in TB
incidence and mortality in South Africa, [9,10] yet TB remains the
most common cause of adult death in South Africa. [11] In 2008 it
was estimated that 60% of those requiring ART in South Africa
were not receiving it. [12] Likewise, an estimated 28% of TB cases
went undetected in 2010 [13].
The HIV epidemic affects individuals in their productive
working years of life. Surveys on mining operations in South
Africa have reported HIV prevalences of 15% to 27%. [14,15] TB
rates in South African gold miners are among the highest in the
world, and HIV/TB co-infection is common. [16] Many
occupational settings provide healthcare for workers, which
includes voluntary counselling and testing (VCT) services, care
for HIV positive employees within a Wellness programme and,
more recently, free ART [17,18].
This study measures trends in mortality in a population of South
African platinum miners from 1992 to 2010, covering the period
before the HIV epidemic until several years after the rollout of
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38598
ART. We estimate cause-specific mortality (using medical records
and findings from autopsies of cardiorespiratory organs) to
describe the impact of HIV, a Wellness programme that includes
ART, and TB on mortality in this population.
Methods
Setting
The study was based on a platinum mine in Rustenburg, North
West Province, South Africa, where HIV seroprevelance was
estimated to be 24.6% in 2002. [14] Medical care is provided free
of charge by the company and includes primary care and hospital
facilities. All miners join a provident fund which provides a death
benefit payable to the employee’s next-of-kin in the event of death
within 12 months of being ‘‘medically boarded’’ (i.e. retired on the
grounds of ill-health). The company’s HIV programme includes
prevention, VCT, and a ‘‘Wellness’’ programme for HIV-positive
employees, through which miners could access ART since April
2003. [17,19] Employees need to be registered on Wellness to
monitor their CD4 counts, clinical status and, where appropriate,
to receive free ART provided by the mining company. During the
period of the study, patients were eligible for ART if they had
a CD4 count of ,250 cells/ml, WHO stage 4, or WHO stage 3
with a CD4 count of ,350 cells/ml. A TB service, which includes
screening, diagnostic tests and treatment, is provided free of
charge and miners diagnosed with TB receive treatment in
accordance with South African National guidelines, through
a dedicated TB clinic.
Data Collection
The study utilised a number of routinely-collected retrospective
databases, with individuals linked by a unique company number.
These included a personnel database with details of employment
dates; medical databases (hospital death register, Wellness
programme, TB clinic, VCT, hospital laboratory); provident fund
records; and the National Institute for Occupational Health
(NIOH) autopsy database, which has included data on cause of
death in a standardised format since 1996. Autopsies of the cardio-
respiratory organs are conducted on miners for compensation
purposes, with the consent of next of kin and regardless of the
clinical cause of death.
Defining the Cohort
Personnel records were used to construct an open cohort of all
semiskilled and unskilled male miners (comprising underground
miners, labourers and surface plant workers). Skilled workers were
excluded as they do not use the mine medical services. Subjects
entered the cohort on 1 January 1992 or on the date of
employment if later than this. They remained in the cohort until
they died, left the mine or until 31 December 2010. The date of
censoring for medically boarded employees was extended by 12
months (or until death, or 31 December 2010 if this occurred
earlier) as these employees remained at risk and under observation
while eligible for the death benefit. We excluded 3792 females
since they comprised a small proportion of the workforce and their
risk behaviours, health service utilisation, and background
mortality rates can differ substantially from males in this manual
labour employment setting. Furthermore, in the early study
period, very few women were employed on the mines making it
difficult to explore time trends.
Determination of Cause of Death and HIV Status at Death
The most likely cause of death was determined using all
available data sources. If multiple causes of death were plausible,
the main cause was determined by the clinical judgement of three
clinicians (including one pathologist), with autopsy findings taking
precedence. For example, a TB death would be one where TB was
identified clinically and/or on autopsy. However, if the autopsy
identified another cause of death then this case would not be
categorised as a TB death despite a clinical diagnosis of TB.
Men were classified as HIV positive if they had a recorded HIV
positive test; if they were identified as HIV positive through the
ART or TB treatment databases; if their medical record or death
certificate stated HIV, AIDS or if a euphemism such as ‘immune
compromised’; or if their cause of death was a clearly AIDS-
related condition (Pneumocystis jirovecii pneumonia (PCP), aspergil-
lus, nocardia pneumonia, cryptococcal disease, oesophageal
candidiasis, lymphadenopathy, interstitial pneumonitis, cytomeg-
alovirus pneumonia, toxoplasmosis, or Kaposi’s sarcoma). All men
who were not known to be positive were classified as ‘HIV
negative or unknown.’
Causes of death were classified into one of four Global Burden
of Disease groups, as described by Bradshaw, et. al.: I)
communicable, II) non-communicable, III) violence and injuries,
and IV) HIV-related. [20] The cause of death was considered to
be HIV-related if the miner was HIV positive and the cause of
death was likely to be related to HIV (e.g. excluding violence or
injury, cardiovascular disease, most malignancies). For example,
TB or bacterial pneumonia in an HIV-positive individual would
be included in HIV/AIDS-related deaths, whereas, in an HIV-
negative or HIV-unknown individual, these would be included in
the communicable diseases group.
Analysis
Data were entered and cleaned, and personal identifiers were
removed. Records were expanded into person years at risk (py) by
calendar year (1992 to 2010) and 10-year age categories. Median
current age was calculated for each year as the man’s age on
January 1st of that year, or on entry to cohort if later. All-cause and
cause-specific mortality rates were calculated by calendar year.
Direct age standardisation was applied, using the average age
distribution for the entire cohort in 10-year age groups as the
standard. Age-adjusted Poisson regression coefficients determined
the average change in rate per year during the study period since
1992. Analyses were conducted using Stata 10.
Ethics Statement
Ethical approval was obtained from the Human Research
Ethics Committee (Medical) of the University of the Witwaters-
rand, South Africa (M041028), and the UCL Research Ethics
Committee, United Kingdom (1641/001). The Committees
specifically addressed issues of consent and confidentiality. Given
the retrospective nature of the study; high mortality; use of routine
databases linked by a unique number; and removal of personal
identifiers prior to analysis, specific written consent for inclusion in
this research was not required. Autopsies were conducted with
written consent from the next of kin, in accordance with the South
African Occupational Diseases in Mines and Works Act. The
project is covered by the UCL Data Protection Registration
(Reference No Z6364106/2008/8/18, Section 19, Research:
Health Research).
Results
The cohort of 41,665 miners was observed for 311,938 person
years (Table 1). There were fluctuations in the median size, age
and duration of employment of the workforce over the period,
including two periods (2005 and 2009) when a number of workers
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accepted voluntary retrenchment packages. The median age of the
cohort was 35.8 years in 1992, reaching 45.3 years by 2005 and
then reducing to 40.9 years by 2010. There were 3863 deaths from
1992 to 2010, giving a crude mortality rate of 12.4/1000py
(95%CI 12.0–12.8). Twelve percent of deaths (n = 450) were in
those who had been medically boarded. If medically boarded men
were censored when they left employment, the overall mortality
rate was 11.0/1000py. Mortality increased with age group: from
5.0/1000py in those aged,25 years, to 6.7, 10.8, 17.4 and 22.6 in
those aged 25–34, 35–44, 45–54 and 55+ years, respectively.
Results from autopsy of cardiorespiratory organs were available
for 36% (n= 1401) of deaths.
Mortality Trends and Causes
Figure 1 shows the crude and age-standardised mortality rate
over time. The all-cause crude mortality rate increased rapidly
from a baseline of 4.9/1000py in 1992 and peaked at 21.1/1000py
in 2003. The mortality rate fluctuated but remained high between
2003 and 2010. Age-standardised mortality followed a similar
pattern, rising from 5.9/1000py in 1992 to 20.2/1000py in 2002,
and fluctuating in the following years.
Figure 2 shows mortality rates over the period 1992 to 2010, in
the four Burden of Disease groups. There were no known HIV/
AIDS-related deaths prior to 1994, with HIV/AIDS-related
mortality increasing rapidly from the mid-1990s, peaking at
14.1/1000py in 2003, dropping to 8.2/1000py by 2006 and
fluctuating in the subsequent four years. Mortality rates remained
stable between 1992 and 2010 for communicable diseases other
than HIV (average change of +2% per year, 95%CI 21%, +4%)
and for non-communicable diseases (21% per year, 95%CI22%,
+1%). Rates of death from violence and injuries declined by an
average of 3% (95%CI 24%,22%) per year over the study
period. TB mortality increased from 0.2/1000py in 1992 to a peak
of 6.7/1000py in 2003, and fluctuating in subsequent years; an
overall increase between 1992 and 2010 of 14% per year (95%CI
+12%, +16%).
Table 2 shows cause of death by HIV status, Wellness
programme registration and time period. Of the 3863 deaths,
78% were from natural causes. Overall, 50% of deaths were HIV/
AIDS-related and 21% were due to TB. In HIV positive miners,
the proportion of deaths attributed to TB increased significantly
over time, from 28% in the pre-ART period to 41% in the post-
ART period (p,0.01). There were no other significant changes in
the proportions of deaths from the different causes among HIV
positive men before and after the rollout of ART. In HIV negative
miners, the proportion of deaths due to TB was 5.4% in the pre-
ART period and 6.2% in the post-ART period (p= 0.6).
Silicosis was identified on autopsy in 70 men. In none of these
was silicosis the cause of death. In one miner, who died in 1992,
the clinical cause of death was recorded on the death register as
silicosis, but we have no further clinical or post-mortem in-
formation.
HIV Programme Registration and ART
Of the 1925 men who died from HIV-related causes (Table 2),
730 (38%) died prior to ART rollout in 2003. Between 2003 and
2010, 3601 HIV-positive men were registered on the Wellness
programme and 2078 started ART (Table 1). The median CD4
count at commencement of ART was 162 cells/mm3. There were
598 HIV-related deaths on the Wellness programme; 35%
(n= 211) had never received ART. Of those HIV-related deaths
that occurred on ART, 38% occurred within 6 months of starting
ART. Of the 1195 who died of HIV-related causes after ART
rollout, 597 (50%) had never been recorded as registered on the
Wellness programme. There were no differences in the distribu-
tion of causes of death between HIV positive men who were
registered on the Wellness programme and those who were not
registered.
Discussion
This study examines the population impact of a Wellness (HIV/
ART) programme, rather than the outcomes of a clinic-based
cohort of patients on ART. It takes into account mortality in the
population as a whole, and includes those who never entered
Wellness, those on ART and those who interrupt ART for a variety
of reasons. This cohort of male South African platinum miners
experienced a rapid increase in mortality from 1996 to 2003 due
to increases in HIV and TB related mortality. Following the
rollout of ART in 2003, there was an initial reduction in all-cause
mortality, but a steady decrease was not sustained and HIV and
TB remained the most common causes of mortality in this
population. We discuss several possible explanations for these
mortality trends: changing composition of the workforce, matu-
ration of the HIV epidemic, occupational and programmatic
factors.
It is well documented that there are differential rates of HIV
mortality by age at infection, [21] and this may partly reflect the
mortality trends observed in this study (although they persisted
after adjusting for current age). The composition of this open
cohort changed over the study period. From 1992 to 2004, the
average age and duration of employment increased each calendar
year, reflecting relatively small net turnover of employees. This
was followed by periods of downsizing, such as the voluntary
retrenchments in 2005 and 2009, and subsequent recruitment of
large numbers of younger men. In addition to changes in the age
structure, it is not known if voluntary retrenchment during these
periods was associated with illness and therefore future mortality.
Interpreting the impact of ART rollout on mortality on
a population level is difficult, since numerous other factors, such
as changes in the population structure also impact on mortality
rates over time. We do not have detailed information at an
individual level for those that started and their clinical histories (eg
treatment regimens, adherence, interruptions) which would be
needed to fully interpret the impact of ART. The observed trends
may also be a function of the natural history of HIV infection and
AIDS in the population, which is dependent on, for example, HIV
incidence and mortality rates by time since seroconversion. Post
ART rollout in 2003 there was an initial reduction in mortality
followed by an increase (spiking in 2009) and subsequent decrease
in all-cause mortality. It is difficult to explain this variation, some
of which may be due to chance with confidence intervals
overlapping. Alternate explanations include health system failures,
such as ‘‘health worker fatigue’’ following extensive human
resources focussing on getting sick individuals on ART, but also
shifting the focus away from TB services, with resultant increase in
TB-specific mortality, reflected in the increasing proportion of
deaths due to TB in later years.
This study has potential limitations. First, trends in all-cause
mortality may be specific to this occupational cohort, but we do
not believe this to be a major limiting factor because the rate of
occupational injury mortality did not change significantly over the
study period. [22] As part of the autopsy of cardiorespiratory
organs, the presence of silicosis is recorded for compensation
purposes. The 70 men with silicosis recorded on autopsy died of
other causes and had probably previously worked in the gold
mining industry where silicosis is much more common. Second, an
occupational cohort, representing only one mine, may not be
Trends in HIV and Tuberculosis Mortality
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representative of the entire population, considering the ‘‘healthy
worker effect’’ and access to relatively good quality medical
services. The age-standardisation in this study used the average
age distribution for the entire cohort in 10-year age groups as the
standard, allowing comparison of trends across the time spectrum.
Although comparison with rates standardised to the 2001 South
African adult male population must be made with caution, these
were very similar (8.1/1000py, compared to 9.5/1000py in 1997,
and 16.3/1000py, compared to 16.7/1000py in 2004. [23]).
Survival by time since HIV seroconversion in gold miners, pre-
ART, has also been shown to be comparable to pre-ART survival
in HIV seroconverter cohorts in developed countries. [24] A third
limitation is that HIV prevalence in the population by year is not
available, and we only have a single point prevalence estimate of
nearly 25% in 2002. [14] We are therefore unable to estimate the
proportion of the HIV-infected workforce on Wellness or on ART.
We recognise that HIV may be underdiagnosed in the cohort and
hence refer to HIV negative or unknown. However, in a setting
with high HIV incidence, it is likely that classifying HIV status on
the basis of the last negative test would result in underestimation of
HIV infection at death, particularly if the test was done some time
before death. This is unlikely to be a major source of bias as deaths
from ‘other communicable’ diseases remain broadly stable
throughout the study period and there are marked differences in
causes of death between those we know to be HIV-positive and the
remaining men. We did consider whether HIV infections and
associated deaths were likely to be missed early in the epidemic.
However, we do not believe this to be the case as mortality from
other communicable diseases did not increase over that time
period, whereas there was a rise in deaths from violence and
injuries.
Health system, programmatic and clinical factors impact on
mortality [8,25,26] and these would have changed over a study
period which spans nearly 20 years. In order for ART to reduce
mortality in a population, HIV-positive individuals need to be
identified, register on an HIV care programme, start on ART at
the appropriate time and continue on the treatment programme.
Mine management has put initiatives in place to promote VCT
services, with nearly universal coverage in later years (97% in
2010). [27] Yet, in this study, half of the HIV-related deaths in the
post-ART era occurred in men who were not registered on the
Wellness programme. Reasons for failure of registration on the
programme may include denial of positive status, use of traditional
medicines, fear of disclosure, concerns over losing employment, or
language difficulties. [28] Although free access to ART is available
through the mining health services, it is also possible that ART was
accessed through public sector programmes by some men. Of
those men who died who were registered on the programme, 35%
had never been on ART. Furthermore, 38% of those who died on
ART died in the early phase of treatment, indicating that they may
have started treatment late. This study is not intended to evaluate
the outcomes of patients on ART. A previous study in these mines
showed a 71% decrease in mortality after 6–12 months of ART,
compared to an historic cohort. [18] Like many other clinic-based
studies, deaths among those who never registered, those who had
been on treatment but were lost to follow up, and those who never
Figure 1. Crude and age standardised mortality rates (all-cause) in cohort, by year, 95% error bars shown.
doi:10.1371/journal.pone.0038598.g001
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received ART, were not included. In contrast, our population-
based study includes all deaths and suggests that the Wellness
programme is having a limited effect at a population level, with no
differences in the proportion of deaths (50%) or the distribution of
deaths between those in Wellness and not.
The contribution of TB-specific mortality in this cohort is
striking. TB was the commonest cause of death in HIV positive
miners, increasing from 28% of deaths in the pre-ART period to
41% in the post-ART period. On a population level, TB-specific
mortality rates increased by an average of 14% per year over two
decades. This coincided with increasing TB rates in other mine
populations (TB incidence in South African gold miners doubled
in HIV negative men and increased 8-fold in HIV positive men
between 1991–3 and 2003–4), [16] and in the South African
population generally (the number of national notified TB cases
increased from 82,539 in 1992 to 396,554 in 2010). [13]
Tuberculosis deaths are preventable deaths. Measures, such as
screening HIV-positive individuals for TB, offering VCT to TB
patients, isoniazid preventive therapy for HIV positive men, and
early initiation of ART in TB/HIV patients, [8,25] have the
potential to substantially reduce mortality. Integration of HIV and
TB programmes could make more efficient use of resources and
help alleviate the burden of TB in people living with HIV, as well
as the population as a whole. [29]
In this employment cohort, HIV and TB mortality rates remain
extremely high, despite the free availability of medical care,
including ART. These trends are at least in part explainable by
changes in recruitment and retention in employment, and by
natural changes in the stage of the HIV epidemic. However, these
factors are not in the control of health services, while HIV and TB
programmes and ART, are. In order to make a significant and
sustained reduction in mortality in this population, expanding and
integrating HIV and TB care and treatment, through programmes
based on growing evidence, [8] is essential.
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